Acta Medica Europa

Second and Third Trimester Screening Tests

Sharma Shah [1]

[1] Specialist of Gynecology and Obstetrics, New Delhi, India

doi: 10.5281/zenodo.10433003

Dear Editor,

Pregnancy is a time of both excitement and uncertainty, with expectant parents bombarded with information about prenatal care and testing options. Among the most discussed are second and third trimester screening tests, aimed at detecting potential chromosomal abnormalities and birth defects in the developing fetus. This letter aims to navigate the information maze for readers, outlining the purpose, limitations, and benefits of these tests while acknowledging the emotional complexities involved (1-4).

The Second Trimester Screen:

A combination of maternal serum markers and nuchal translucency ultrasound, it estimates the risk for conditions like Down syndrome, Trisomy 13, and spina bifida. Non-invasive and low-risk, it does not diagnose but provides valuable information for further confirmatory testing if indicated. Positive results often lead to amniocentesis or chorionic villus sampling, invasive procedures with a small but real risk of miscarriage (4-7).

The Third Trimester Screen:

Primarily an ultrasound examination at 28-32 weeks, focusing on fetal anatomy and growth. Can detect structural anomalies, growth discrepancies, and potential complications like placental insufficiency. Does not replace routine ultrasounds throughout pregnancy but offers a detailed assessment at a later stage (4-7).

Both tests are optional, and decisions should be made in consultation with healthcare providers after informed discussion of benefits, limitations, and potential emotional consequences. Individual considerations such as family history, age, and personal values should be factored into the decision-making process. Genetic counseling can provide invaluable support in understanding test results and navigating the emotional complexities involved. Regardless of test outcomes, focusing on prenatal care, positive health habits, and maintaining emotional well-being remains paramount throughout pregnancy. A supportive medical team and access to appropriate resources are crucial for managing any identified risks or concerns. Healthcare providers must ensure clear communication, offering unbiased information and respecting individual choices. Researchers should constantly refine screening tests, minimizing false positives and negatives while maximizing early detection of potential issues. Societal support for all pregnancy outcomes, regardless of test results, is essential for creating a safe and informed environment for expectant parents (1-5).

In conclusion, second and third trimester screening tests offer valuable tools for prenatal care, but understanding their limitations and navigating the emotional complexities requires a collaborative approach. By prioritizing clear communication, ongoing research, and societal support, we can empower expectant parents to make informed decisions and experience a healthy and fulfilling pregnancy.

REFERENCES

1. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Prabhu M, Kuller JA, Biggio JR. Society for Maternal-Fetal Medicine Consult Series #57: Evaluation and management of isolated soft ultrasound markers for aneuploidy in the second trimester: (Replaces Consults #10, Single umbilical artery, October 2010; #16, Isolated echogenic bowel diagnosed on second-trimester ultrasound, August 2011; #17, Evaluation and management of isolated renal pelviectasis on second-trimester ultrasound, December 2011; #25, Isolated fetal choroid plexus cysts, April 2013; #27, Isolated echogenic intracardiac focus, August 2013). Am J Obstet Gynecol. 2021;225(4):B2-B15. doi:10.1016/j.ajog.2021.06.079
2. Mirbeyk M, Saghazadeh A, Rezaei N. A systematic review of pregnant women with COVID-19 and their neonates. Arch Gynecol Obstet. 2021;304(1):5-38. doi:10.1007/s00404-021-06049-z
3. Savasan ZA, Goncalves LF, Bahado-Singh RO. Second- and third-trimester biochemical and ultrasound markers predictive of ischemic placental disease. Semin Perinatol. 2014;38(3):167-176. doi:10.1053/j.semperi.2014.03.008

Received: 15 August 2023, Accepted: 19 August 2023, Published: 21 August 2023

Corresponding author: Sharma Shah. Specialist of Gynecology and Obstetrics, New Delhi, India. sharma.shah.md@gmail.com

4. Wertaschnigg D, Rolnik DL, Nie G, et al. Second- and third-trimester serum levels of growth-differentiation factor-15 in prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2020;56(6):879-884. doi:10.1002/uog.22070

5. Pagan M, Monson J, Strebeck R, Edwards S, Magann EF. Subchorionic Hemorrhage in the Second and Third Trimesters of Pregnancy: A Review. Obstet Gynecol Surv. 2022;77(12):745-752. doi:10.1097/OGX.0000000000001082

6. Lesser HT, D'Adamo C, O'Reilly G, Arrabal P, Ehsanipoor RM. Diagnosis of mid-second trimester fetal growth restriction and associated outcomes. J Matern Fetal Neonatal Med. 2022;35(25):10168-10172. doi:10.1080/14767058.2022.2122042

7. Caradeux J, Eixarch E, Mazarico E, Basuki TR, Gratacós E, Figueras F. Second- to third-trimester longitudinal growth assessment for prediction of small-for-gestational age and late fetal growth restriction. Ultrasound Obstet Gynecol. 2018;51(2):219-224. doi:10.1002/uog.17471